Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals

Annals of Internal Medicine

Volumn 143, Issue 10, 2005, Pages

  Clifford, David B ^a   Evans, Scott ^b   Yang, Yijun ^b   Acosta, Edward P ^b   Goodkin, Karl ^b   Tashima, Karen ^b   Simpson, David ^b   Dorfman, David ^b   Ribaudo, Heather ^b   Gulick, Roy M ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; EFAVIRENZ; SEDATIVE AGENT;

ADULT; ANXIETY DISORDER; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIGIT SYMBOL SUBSTITUTION TEST; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MOOD DISORDER; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; NEUROTOXICITY; PATIENT SELECTION; PRIORITY JOURNAL; PSYCHOLOGIC TEST; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SLEEP; SYMPTOMATOLOGY; VIVID DREAM;

EID: 28144452516     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-143-10-200511150-00008     Document Type: Article

References (36)

1. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999;341:1865-73. [PMID: 10601505]
2. U.S. Department of Health and Human Services. Panel on Clinical Practices for Treatment of HIV infection: Guidelines for the Use of Antiretroviral Agents to HIV-infected Adults and Adolescents. Washington, DC: Department of Health and Human Services; 2005.
3. Sustiva (efavirenz) [monograph on-line]. New York: Bristol Myers Squibb; 2002. Available from PDR.net, Montvale, NJ. Accessed 22 September 2005.
4. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA 3rd, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350:1850-61. [PMID: 15115831]
5. Wechsler D. Wechsler Adult Intelligence Scale (WAIS-III) Administration and Scoring Manual. 3rd ed. San Antonio, TX: The Psychological Corp.; 1997.
6. War Department Adjutant General's Office. Army Individual Test Battery. Manual of Direction and Scoring. Washington, DC: War Department; 1944.
7. Reitan RR, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery. 2nd ed. Tucson, AZ: Neuropsychology Pr; 1995.
8. Wechsler D. Wechsler Adult Intelligence Scale Revised (WAIS-R) Manual. New York: Psychological Corp.; 1981.
9. Lezak MD. Neuropsychological Assessment. 2nd ed. New York: Oxford Univ Pr; 1983.
10. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193-213. [PMID: 2748771]
11. Spielberger CD. State-Trait Anxiety Inventory for Adults (Form Y). Redwood City, CA: Mind Garden, Inc.; 1983.
12. Radloff LL. The CES-D: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385-401.
13. Turner ML, Reed-Walker K, King JR, Acosta EP. Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;784:331-41. [PMID: 12505781]
14. Lehmann EL. Nonparametrics: Statistical Methods Based on Ranks. San Francisco: Holden-Day; 1975.
15. Daves CS. Statistical Methods for the Analysis of Repeated Measurements. New York: Springer Publishing; 2002.
16. Schmitt FA, Bigley JW, McKinnis R, Logue PE, Evans RW, Drucker JL. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med. 1988;319:1573-8. [PMID: 3059187]
17. Sidtis JJ, Gatsonis C, Price RW, Singer EJ, Collier AC, Richman DD, et al. Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group. Ann Neurol. 1993;33:343-9. [PMID: 8489204]
18. Ferrando S, van Gorp W, McElhiney M, Goggin K, Sewell M, Rabkin J. Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function. AIDS. 1998;12:F65-70. [PMID: 9631133]
19. Sacktor NC, Skolasky RL, Lyles RH, Esposito D, Selnes OA, McArthur JC. Improvement in HIV-associated motor slowing after antiretroviral therapy including protease inhibitors. J Neurovirol. 2000;6:84-8. [PMID: 10787000]
20. von Giesen HJ, Köller H, Theisen A, Arendt G. Therapeutic effects of nonnucleoside reverse transcriptase inhibitors on the central nervous system in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2002;29:363-7. [PMID: 11917240]
21. Ribaudo H., Clifford D., Gulick R., Shikuma C, Klingman K, Snyder S., et al. Relationships between efavirenz pharmacokinetics, side effects, drug discontinuation, virologic response, and race: Results from ACTG A5095/A5097s. Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health; 2004.
22. Fumaz CR, Tuldrà A, Ferrer MJ, Paredes R, Bonjoch A, Jou T, et al. Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. J Acquir Immune Defic Syndr. 2002;29:244-53. [PMID: 11873073]
23. Lochet P, Peyriere H, Lotthé A, Mauboussin JM, Delmas B, Reynes J. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med. 2003;4:62-6. [PMID: 12534961]
24. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:71-5. [PMID: 11192870]
25. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18:2391-400. [PMID: 15622315]
26. Landovitz R, Winkelman J, Yawetz S, Koziol C, Sax P. Efavirenz increases slow-wave sleep [abstract]. Proceedings of the 10th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health; 2003:314.
27. Gallego L, Barreiro P, del Río R, González de Requena D, Rodríguez-Albariño A, González-Lahoz J, et al. Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz. Clin Infect Dis. 2004;38:430-2. [PMID: 14727217]
28. Puzantian T. Central nervous system adverse effects with efavirenz: case report and review. Pharmacotherapy. 2002;22:930-3. [PMID: 12126226]
29. Sabato S, Wesselingh S, Fuller A, Ray J, Mijch A. Efavirenz-induced catatonia [Letter], AIDS. 2002;16:1841-2. [PMID: 12218403]
30. Peyriere H, Mauboussin JM, Rouanet I, Fabre J, Reynes J, Hillaire-Buys D. Management of sudden psychiatric disorders related to efavirenz [Letter]. AIDS. 2001;15:1323-4. [PMID: 11426084]
31. von Giesen HJ, Köller H, de Nocker D, Haslinger BA, Arendt G. Long-term safety and efficacy of NNRTI within the central nervous system. HIV Clin Trials. 2003;4:382-90. [PMID: 14628281]
32. de la Garza CLS, Paoletti-Duarte S, García-Martín C, Gutiérrez-Casares JR. Efavirenz-induced psychosis [Letter]. AIDS. 2001;15:1911-2. [PMID: 11579266]
33. Blanch J, Martínez E, Rousaud A, Blanco JL, Garciá-Viejo MÁ, Peri JM, et al. Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. J Acquir Immune Defic Syndr. 2001;27:336-43. [PMID: 11468421]
34. Poulsen HD, Lublin HK Efavirenz-induced psychosis leading to involuntary detention [Letter]. AIDS. 2003;17:451-3. [PMID: 12556706]
35. Treisman GJ, Kaplin AI. Neurologic and psychiatric complications of antiretroviral agents [Editorial]. AIDS. 2002;16:1201-15. [PMID: 12045485]
36. Maxwell S, Scheftner WA, Kessler HA, Busch K. Manic syndrome associated with zidovudine treatment [Letter]. JAMA. 1988;259:3406-7. [PMID: 3163740]